Publications by authors named "J Vargova"

The presence of key hypoxia regulators, namely, hypoxia-inducible factor (HIF)-1α or HIF-2α, in tumors is associated with poor patient prognosis. Hypoxia massively activates several genes, including the one encoding the BCRP transporter that proffers multidrug resistance to cancer cells through the xenobiotic efflux and is a determinant of the side population (SP) associated with cancer stem-like phenotypes. As natural medicine comes to the fore, it is instinctive to look for natural agents possessing powerful features against cancer resistance.

View Article and Find Full Text PDF

Berkeleylactone A is a potent 16-membered macrolactone antibiotic, recently isolated from a coculture of Berkeley Pit Lake fungi. Although its antimicrobial activity has already been investigated, little is known about the structure-activity relationship. Based on our previous synthetic studies, a series of berkeleylactone A derivatives were synthesized and evaluated for their antimicrobial activities against methicillin-sensitive and methicillin-resistant (MRSA) strains.

View Article and Find Full Text PDF

It is more than sixty years since the era of modern photodynamic therapy (PDT) for cancer began. Enhanced selectivity for malignant cells with a reduced selectivity for non-malignant cells and good biocompatibility along with the limited occurrence of side effects are considered to be the most significant advantages of PDT in comparison with conventional therapeutic approaches, e.g.

View Article and Find Full Text PDF

Healthcare-associated infections (HAIs) are caused by nosocomial pathogens. HAIs have an immense impact not only on developing countries but also on highly developed parts of world. They are predominantly device-associated infections that are caused by the planktonic form of microorganisms as well as those organized in biofilms.

View Article and Find Full Text PDF

A series of novel C4-C7-tethered biscoumarin derivatives (-) linked through piperazine moiety was designed, synthesized, and evaluated biological/therapeutic potential. Biscoumarin was found to be the most effective inhibitor of both acetylcholinesterase (AChE, IC = 6.30 µM) and butyrylcholinesterase (BChE, IC = 49 µM).

View Article and Find Full Text PDF